CVD drug discovery biomarker & targets

Coordinator:		Dr. Thomas Krahn
Institution:		Bayer Schering Pharma GDD Target Discovery- Translational Medicine & Biomarker
Homepage:		www.bayerhealthcare.com/scripts

Biomarker identification and target validation for the development of specialized CVD treatments for chronic kidney disease (CKD) patients and for CVD patients in general: This subproject TP6 aims at the application and translation of the results obtained in the subprojects TP1- TP6. Identified known mediators and newly discovered mediators in body fluids correlating with the progression of CVD in CKD patients will be evaluated as possible drug targets and as biomarkers. Furthermore we will perform preclinical in vivo pharmacology tests with identified and validated mediators of CVD in CKD in suitable animal models. The results from the preclinical studies and analyses of clinical samples obtained from CKD and CVD patients and matched controls will be used to generate a complete translational medicine data set for biomarker and target qualification.